Dr. Macleod provides a strong operational background in the pharmaceutical and biotechnology industries, where he previously held senior management positions over a 15-year career at Serono, Abbott Laboratories and Beecham Pharmaceuticals. Prior to joining Paul Capital Partners, Dr. Macleod was a Venture Partner at Schroder Ventures Life Sciences where he was responsible for deal sourcing, evaluation and negotiation of pharmaceutical investment opportunities. Dr. Macleod earned his Ph.D. from the University of York, UK and his B.Sc. with honors in Biology from the University of Manchester, UK.
About Paul Capital Partners and Paul Capital Healthcare
Founded in 1991, Paul Capital manages $6.6 billion in capital commitments for its three investment platforms that include private equity secondaries, healthcare royalty and revenue interests, and venture capital fund of funds. The firm has offices in Hong Kong, London, New York, Paris, San Francisco, Sao Paulo and Toronto.
Through its funds, Paul Capital Healthcare is one of the largest
dedicated healthcare investors globally, with more than $1.4 billion in
equity capital commitments and debt facilities under management. Combined,
the Paul Capital Healthcare funds have invested more than $940 million in
the pharmaceutical, biotechnology, and medical device sectors. These
investments are focused on commercial stage companies and products, and
consist of investments in the form of royalties, revenue interests, debt
and equity. Additional information on Paul Capital Healthcare can be found
Paul Capital Partners
Ken Macleod, Partner
Joshua Glaser, Director of Investor Relations'/>"/>
|SOURCE Paul Capital Partners|
Copyright©2008 PR Newswire.
All rights reserved